Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9930038 | 1.00 | MME (0.74) | MMEMMEL1 | |
| SCHEMBL9938136 | 1.00 | MME (0.74) | MMEMMEL1 | |
| SCHEMBL16930482 | 0.90 | MME (0.70) | MME | |
| SCHEMBL9937084 | 0.86 | MME (0.86) | MMEMMEL1 | |
| SCHEMBL18724706 | 0.86 | MME (0.86) | MMEMMEL1 | |
| SCHEMBL23089722 | 0.86 | MME (0.86) | MMEMMEL1 | |
| SCHEMBL9930172 | 0.86 | MME (0.86) | MMEMMEL1 | |
| SCHEMBL23089774 | 0.85 | MME (1.00) | MME | |
| SCHEMBL9938807 | 0.85 | MME (1.00) | MME | |
| SCHEMBL19788081 | 0.85 | MME (0.55) | MMEMMEL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11261197-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-03-01 | — | — | US | claimed |
| US-20210079017-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11261197-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885MMEL1 237/4885 |
| US-20210079017-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885MMEL1 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.